Magnetically triggered release of molecular cargo from iron oxide nanoparticle loaded microcapsules.
Carregal-Romero S, Guardia P, Yu X, Hartmann R, Pellegrino T, Parak WJ.
Nanoscale. 2015; 7: 570-576. FI: 7.394 (Q1).
Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A, Gutiérrez-Rivera A, López-Pestaña A, del Alcázar E, Zubizarreta J, Vildosola S, Arregui MA, Sarasqueta C, Lobo C, Tuneu A.
Actas Dermosifiliogr. 2015; 106: 483-492. FI: 0.000 (Q0).
Myeloid disorders in Practice. MicroRNAs: back to basics.
Lawrie CH.
MicroRNAs: back to basics. 2012; 6 (2): 3-5.
A phase III PETHEMA/GEM randomised trial of post-transplant maintenance in multiple myeloma: superiority of bortezomib. Bone Marrow Transplant.
Rosinol L, Cibeira MT, Mateos MV, Martínez J, Oriol A, Teruel AI, Hernández D, López Jiménez J, De la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández M, De Arriba F, Alegre A, Lahuerta JJ, San Miguel J, Blade J.
Bone Marrow Transplant. 2012; 47: 2-0. FI: 3.746 (Q1).
A Survey of the Perceived Quality of Patient Care in a Radiation Oncology Service: Results From 2002-2011.
Eguiguren Bastida M, Minguez J, Blanco C, Urraca J, Querejeta A, Uranga I, Ciria J, Rodríguez G, Caffiero S, Guimon E.
Int. J. Radiat. Oncol. Biol. Phys. 2012; 84: 541-0. FI: 4.105 (Q1).
Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?.
Ballabio E, Armesto M, Breeze CE, Manterola L, Arestin M, Tramonti D, Hatton CSR, Lawrie CH.
Blood Cancer Journal. 2012; 2: -0. FI: 0.000 (Q0).
GEM Cooperative Study Grp, PETHEMA Cooperative Study Grp. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
Paiva B, Gutiérrez NC, Chen X, Vidriales MB, Montalban MA, Rosinol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ, Fernández-Redondo E, De Arriba F, Palomera L, Bengoechea E, Terol MJ, De Paz R, Martín A, Hernández J, Orfao A, Lahuerta JJ, Blade J, Pandiella A, San Miguel JF.
Leukemia. 2012; 26: 1862-1869. FI: 9.561 (Q1).
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial.
Llombart-Cussac A, Ruiz A, Anton A, Barnadas A, Antolin S, Ales-Martínez JE, Álvarez I, Andres R, García Sáenz JA, Lao J, Carrasco E, Camara C, Casas I, Martín M.
Cancer. 2012; 118: 241-247. FI: 4.771 (Q1).
Spanish Cooperative Grp Treatment. First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study.
Díaz-Rubio E, Gómez-España A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallen M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Anton A, Aranda E.
Oncologist. 2012; 17: 15-25. FI: 3.812 (Q2).
SENEC. Functions and organisation of a neuro-oncology committee in hospitals with a neurosurgery service
Arrazola M, Bollar A, Sampron N, Ruiz I, Egaña L, Querejeta A, Villanua J, Liceaga G, Caballero MC, Urtasun M, Urculo E.
Neurocirugía. 2012; 23: 151-156. FI: 0.540 (Q4).
PETHEMA Cooperativa Study Grp, GEM Cooperativa Study Grp. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Paiva B, Gutiérrez NC, Rosinol L, Vidriales MB, Montalban MA, Martínez-López J, Mateos MV, Cibeira MT, Cordon L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, De la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martín A, Hernández MT, Lahuerta JJ, Blade J, San Miguel JF.
Blood. 2012; 119: 687-691. FI: 9.898 (Q1).
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Gómez-Martín C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, Safont MJ, Falco E, Lacasta A, Reboredo M, Aparicio J, Duenas R, Llanos Muñoz M, Regueiro P, Sánchez-Vines E, López López R.
Clin. Transl. Oncol. 2012; 14: 689-697. FI: 1.327 (Q4).
Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining.
Lawrie CH, Ballabio E, Soilleux E, Sington J, Hatton CSR, Dirnhofer S, Tzankov A.
Histopathology. 2012; 61: 18-25. FI: 3.082 (Q1).
Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial.
Rosinnol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, De La Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández, MT, De Arriba F, Alegre A, Cibeira MT, Mateos MV, Martínez J, Lahuerta JJ, San Miguel JF, Blade J
Blood. 2012; 120: -0. FI: 9.898 (Q1).
